Autologous Platelet-Rich Plasma (PRP): Autologous Platelet-Rich Plasma (PRP) will be injected intra-articularly in patients with knee osteoarthritis
Conditioned serum (CS): Autologous conditionedserum (CS) will be injected intra-articularly in patients with knee osteoarthritis
Study summary
The effects of single dose injection of platelet rich plasma or conditioned serum in the knee joint in patients with knee osteoarthritis will be compared
Eligibility
Sex
ALL
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. Diagnosis of knee osteoarthritis according to ACR criteria at least 6 months ago.
2. Being between grade 1-2 according to the Kellgren-Lawrence radiological classification.
3. Not having had PRP injection in the last year.
4. Knee pain ≥ 5 according to the visual pain scale.
Exclusion Criteria:
1. Those with significant neurological or cardiovascular disorders.
2. Those with active thrombovascular disease.
3. Those with joint or skin infections.
4. Those who have recently had an infectious disease.
5. Those infected with Hepatitis B, C, and HIV.
6. Those who have received intra-articular knee injections (hyaluronic acid, PRP, corticosteroids, and others) within the last year.
7. Those who use oral corticosteroids.
8. Those who have used NSAIDs within the last week.
9. Those who have used anti-platelet or anti-aggregant drugs within the last week.
10. Those with coagulation disorders.
11. Those with hemoglobin \<10 g/dl and platelet count \<100,000
12. Those with cancer.
13. Pregnant or breastfeeding women, drug addicts.
14. Those scheduled for knee surgery or arthroscopy, or those who have undergone knee surgery or arthroscopy.
15. Those with diseases causing secondary osteoarthritis:
1. post-traumatic,
2. congenital or developmental diseases
1. Local diseases (leg length discrepancy, varus, valgus deformities, hypermobility syndromes, scoliosis)
2. Generalized diseases (Bone dysplasias, Metabolic disorders (hemochromatosis, ochronosis, Gaucher disease, hemoglobinopathy, Ehlers-Danlos disease))
3. Calcium storage diseases (calcium pyrophosphate storage disease, etc.)
4. Other bone and joint diseases (avascular necrosis, rheumatoid arthritis, gouty arthritis, septic arthritis, Paget's disease, osteoporosis, osteochondritis)
5. Other diseases
1. Endocrine diseases (Diabetes mellitus, acromegaly, hypothyroidism, hyperthyroidism)
2. Neuropathic arthropathy (Charcot joint)
3. Other (Frost, Kashin-Beck disease, Caisson disease) -
Primary outcome measure(s)
Visual pain scale score — Visual pain scale score (min 0-max 10) will be measured at the beginning ofthe study, 1 week, 1month and 3 months after the injection. Visual pain scale score (min 0-max 10), higher scores indicate better results
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.